Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Moleculin Biotech (0K2H) Price & Analysis

0K2H Stock Chart & Stats

$5.32$0.00(0.00%)
At close: 4:00 PM EDT
$10$20$30$4027 Jul10 Aug24 Aug8 Sep21 Sep5 Oct19 Oct
Day’s Range
$5.32 - $5.32
52-Week Range
$4.66 - $315.00
Previous Close
$5.32
Volume
44.88K
Average Volume (3M)
770
Market Cap
$8.29M
Enterprise Value
$8.88M
Total Cash (Recent Filing)
$7.26M
Total Debt (Recent Filing)
$292.00K
Price to Earnings (P/E)
―
Beta
0.40
Next Earnings
Mar 19, 2027
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Late-stage Clinical Progress

Completing Part A dosing in a pivotal Phase 2/3 trial demonstrates meaningful execution and moves Annamycin closer to a data-driven regulatory decision. The broader 90-patient dataset should clarify efficacy, safety, and dose selection across important relapsed or refractory AML populations.

Potential Cardiac Safety Differentiation

The reported absence of treatment-related cardiotoxicity across five trials could differentiate Annamycin from conventional anthracyclines, whose use is constrained by cardiac toxicity. If confirmed in ongoing development, this safety profile may support broader adoption and sustained clinical relevance.

Long-dated Intellectual Property

Patent protection extending to 2040 provides a potentially durable exclusivity period for a lung-targeted Annamycin formulation. Combined with ongoing clinical development, this protection could preserve future commercial differentiation and support development across additional oncology indications if efficacy is validated.

Bears Say

No Commercial Revenue And Persistent Losses

Moleculin remains pre-commercial, with no reported revenue to offset a sizable operating cost base and persistent losses. Until a candidate is approved and commercialized, the company lacks operating leverage and must continue funding clinical development without internally generated sales.

Continued Cash Burn And Financing Dependence

Consistently negative operating and free cash flow shows that current operations are not self-funding. Continued clinical spending therefore requires external capital, leaving the company exposed to financing conditions and creating a durable risk that future funding may increase dilution or constrain development plans.

Equity Dilution And Listing Risk

Recent equity financing and accompanying warrants expand potential dilution for existing holders while funding remains necessary. Separately, the Nasdaq minimum-bid deficiency creates uncertainty around continued exchange listing and could impair investor access and future capital-raising flexibility.

Moleculin Biotech News

0K2H FAQ

What was Moleculin Biotech’s price range in the past 12 months?
Moleculin Biotech lowest share price was $4.66 and its highest was $315.00 in the past 12 months.
What is Moleculin Biotech’s market cap?
Moleculin Biotech’s market cap is $8.29M.
When is Moleculin Biotech’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Moleculin Biotech’s earnings last quarter?
Moleculin Biotech released its earnings results on Aug 14, 2026. The company reported -$28 earnings per share for the quarter, beating the consensus estimate of -$31.067 by $3.067.
Is Moleculin Biotech overvalued?
According to Wall Street analysts Moleculin Biotech’s price is currently Undervalued.
Does Moleculin Biotech pay dividends?
Moleculin Biotech does not currently pay dividends.
What is Moleculin Biotech’s EPS estimate?
Moleculin Biotech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Moleculin Biotech have?
Moleculin Biotech has 1,050,000 shares outstanding.
What happened to Moleculin Biotech’s price movement after its last earnings report?
Moleculin Biotech reported an EPS of -$28 in its last earnings report, beating expectations of -$31.067. Following the earnings report the stock price went up 13.36%.
Which hedge fund is a major shareholder of Moleculin Biotech?
Currently, no hedge funds are holding shares in GB:0K2H
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology